High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan

2019 ◽  
Vol 39 (10) ◽  
pp. 1803-1810 ◽  
Author(s):  
Hiroe Sato ◽  
Naoki Kondo ◽  
Ayako Wakamatsu ◽  
Daisuke Kobayashi ◽  
Takeshi Nakatsue ◽  
...  
2012 ◽  
Vol 94-B (3) ◽  
pp. 385-390 ◽  
Author(s):  
R. N. Thompson ◽  
J. R. A. Phillips ◽  
S. H. J. McCauley ◽  
J. R. M. Elliott ◽  
C. G. Moran

Author(s):  
Atie Moghtadaie ◽  
Seyed Amir Miratashi Yazd ◽  
Ahmad Salimzadeh

Background: Bisphosphonates are the most widely prescribed agents for the treatment of postmenopausal osteoporosis and other metabolic bone diseases. Atypical femoral fractures in bisphosphonate-treated patients have raised concerns regarding the long-term safety of this class of medications. Case Presentation: In this study, we report two patients suffering from fractures while receiving biphosphonates; a postmenopausal patient with rheumatoid arthritis and a history of long-term use of bisphosphonates and glucocorticoids presenting with multiple fractures as case one and another 52-year-old female patient diagnosed with Systemic Lupus Erythematosus (SLE) who suffered from a femoral shaft fracture without any history of prior traumatic incidents as case two. Conclusions: Considering the low risk for atypical femoral fractures, further careful screening for these types of fractures should be undertaken. In addition, in order to lower the rate of fractures in patients on long-term bisphosphonate therapy, assessment of patients’ contralateral side should be considered to prevent further fractures, especially in patients with prodromal pain.


2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Kosuke Hamahashi ◽  
Toshihiro Noguchi ◽  
Yoshiyasu Uchiyama ◽  
Masato Sato ◽  
Masahiko Watanabe

Bilateral atypical femoral fractures (AFFs) are relatively rare. In this report, we retrospectively researched clinical features and outcomes of bilateral AFFs treated at our institution. We previously treated 4 patients (8 limbs) with intramedullary nailing for complete AFFs (6 limbs) and incomplete AFFs (2 limbs). The mean age at the first operation was 53.3 years, and all patients were female. Of the 4 patients, two had breast cancer, and another two had systemic lupus erythematosus. Three of them received bisphosphonates, and 2 received denosumab, proton pump inhibitor, or glucocorticoid therapy. Only 2 of 6 cases of incomplete AFFs had prodromal pain before progressing to complete fracture. The mean interval from the first surgery to contralateral fracture or prophylactic surgery was 16 months. Radiographically, complete bone union was achieved in 6 limbs. However, a small gap at the lateral cortex of fracture site remained in 2 limbs. Finally, all of the patients were pain-free and able to walk without a cane. It is absolutely necessary to confirm contralateral femoral conditions; however, prediction of progression to complete fracture based solely on prodromal pain was difficult. Therefore, we should advise patients about the danger of progression to complete AFFs even if they are asymptomatic, and a prophylactic surgery should be performed after obtaining informed consent.


Sign in / Sign up

Export Citation Format

Share Document